Omeprazolo Sos (Omeprazole Sodium)

Omeprazole, the active ingredient in Omeprazolo Sos, is a proton pump inhibitor presented as a 20mg/10ml oral solution for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazolo Sos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazolo Sos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazolo Sos is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastroesophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal erosion. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Erosive esophagitis: aids the healing of erosive damage in the esophagus. - NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Omeprazolo Sos may cause a range of adverse reactions. Most are mild and resolve after discontinuation.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild stomach discomfort. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis associated with antibiotic‑related dysbiosis. - Acute interstitial nephritis: kidney inflammation presenting with rash, fever, and impaired renal function. - Osteoporosis‑related fractures: increased risk of hip, wrist or vertebral fractures with long‑term use. - Hypomagnesemia: low serum magnesium levels causing muscle cramps or cardiac arrhythmia. - Stevens‑Johnson syndrome: rare severe skin reaction with blistering and mucosal involvement. - Anaphylaxis: immediate hypersensitivity reaction with airway compromise.

Before prescribing Omeprazolo Sos, clinicians should consider several safety aspects.

- Assess renal and hepatic function: adjust use in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for bone density loss and magnesium levels. - Use the lowest effective dose: limit duration to the shortest period needed. - Pregnancy and lactation: evaluate risk‑benefit ratio. - Store at below 25°C: keep in the original container, protect from moisture and light.

Omeprazolo Sos can affect the absorption and metabolism of several medicines. Clinicians should evaluate these interactions carefully.

Major Interactions (Avoid): - Ketoconazole and itraconazole: reduced antifungal efficacy due to decreased gastric acidity. - Atazanavir: markedly lowered plasma concentrations, compromising HIV treatment. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Digoxin: higher serum levels may occur, necessitating dose adjustment. - Methotrexate: reduced clearance can raise toxicity risk. - Phenytoin: altered metabolism may affect seizure control.